Lifeloc Reports Second Quarter 2025 Results
Lifeloc Technologies (OTCID:LCTC), a breath alcohol and drug testing device manufacturer, reported Q2 2025 financial results with net revenue of $2.219 million, down 7% year-over-year, and a net loss of $(394) thousand or $(0.14) per share.
The company maintained a gross margin of 41.7% while investing heavily in R&D ($623 thousand) for SpinDx development. Their strategic focus remains on the SpinDx technology platform for rapid drug detection, with commercial launch projected for early 2026. The platform has demonstrated effectiveness in detecting multiple drugs including THC, cocaine, and fentanyl.
Lifeloc has been approved for trading on the OTCID market tier, upgrading from OTC Pink Current Market as of July 1, 2025.
Lifeloc Technologies (OTCID:LCTC), produttrice di dispositivi per il test dell'alito per alcol e droghe, ha comunicato i risultati finanziari del 2掳 trimestre 2025 con ricavi netti di $2.219 million, in calo del 7% su base annua, e una perdita netta di $(394) mila ovvero $(0.14) per azione.
L'azienda ha mantenuto un margine lordo del 41,7% continuando per貌 a investire significativamente in R&S ($623 mila) per lo sviluppo di SpinDx. La strategia rimane focalizzata sulla piattaforma tecnologica SpinDx per il rilevamento rapido di sostanze, con lancio commerciale previsto per i primi mesi del 2026. La piattaforma ha dimostrato efficacia nel rilevare pi霉 droghe, tra cui THC, cocaina e fentanyl.
Lifeloc 猫 stata autorizzata alla negoziazione sul livello di mercato OTCID, salendo dall'OTC Pink Current Market a partire dal 1掳 luglio 2025.
Lifeloc Technologies (OTCID:LCTC), fabricante de dispositivos de prueba de alcohol en aliento y detecci贸n de drogas, inform贸 sus resultados financieros del 2T 2025 con ingresos netos de $2.219 million, una ca铆da del 7% interanual, y una p茅rdida neta de $(394) mil o $(0.14) por acci贸n.
La compa帽铆a mantuvo un margen bruto del 41,7% mientras invert铆a fuertemente en I+D ($623 mil) para el desarrollo de SpinDx. Su enfoque estrat茅gico sigue en la plataforma tecnol贸gica SpinDx para la detecci贸n r谩pida de drogas, con lanzamiento comercial proyectado a principios de 2026. La plataforma ha mostrado eficacia en la detecci贸n de m煤ltiples drogas, incluyendo THC, coca铆na y fentanilo.
Lifeloc ha sido aprobada para cotizar en el nivel de mercado OTCID, ascendiendo desde OTC Pink Current Market desde el 1 de julio de 2025.
Lifeloc Technologies (OTCID:LCTC), 順疙潯 鞎岇綌鞓� 氚� 鞎诫 瓴�靷� 鞛ル箘 鞝滌“鞐呾泊電� 2025雲� 2攵勱赴 鞁れ爜鞚� 氚滍憸頃橂┌ 靾滊Г於� $2.219 million毳� 旮半頃� 鞝勲厔 霃欔赴 雽�牍� 7% 臧愳唽頄堦碃, 靾滌啇鞁れ潃 $(394)觳� 霕愲姅 欤茧嫻 $(0.14)鞓�鞀惦媹雼�.
须岇偓电� 齑濎澊鞚惦 41.7%鞚� 鞙犾頃橂┐靹滊弰 SpinDx 臧滊皽鞚� 鞙勴暣 鞐瓣惮臧滊皽(R&D)鞐� $623觳滌潉 歆戩 韴瀽頄堨姷雼堧嫟. 鞝勲灥鞝� 齑堨爯鞚� 鞁犾啀 鞎诫 韮愳鞖� SpinDx 旮办垹 頂岆灚韽检棎 鞛堨溂氅�, 靸侅梾鞝� 於滌嫓電� 2026雲� 齑堧 鞓堨儊霅╇媹雼�. 頃措嫻 頂岆灚韽检潃 THC, 旖旍勾鞚�, 韼滍儉雼� 霌� 鞐煬 鞎诫 瓴�於滌棎 須臣毳� 氤挫榾鞀惦媹雼�.
Lifeloc鞚� 2025雲� 7鞗� 1鞚茧秬搿� OTC Pink Current Market鞐愳劀 靸來枼霅橃柎 OTCID 鞁滌灔 霌标笁鞐愳劀 瓯半灅 鞀轨澑鞚� 氚涭晿鞀惦媹雼�.
Lifeloc Technologies (OTCID:LCTC), fabricant d'appareils de d茅pistage de l'alcool expir茅 et des drogues, a publi茅 ses r茅sultats du 2e trimestre 2025 avec un chiffre d'affaires net de $2.219 million, en baisse de 7% d'une ann茅e sur l'autre, et une perte nette de 394 000 $ soit 0,14 $ par action.
La soci茅t茅 a maintenu une marge brute de 41,7% tout en investissant massivement en R&D (623 000 $) pour le d茅veloppement de SpinDx. Sa strat茅gie reste ax茅e sur la plateforme technologique SpinDx pour la d茅tection rapide de drogues, avec un lancement commercial pr茅vu d茅but 2026. La plateforme a d茅montr茅 son efficacit茅 pour d茅tecter plusieurs drogues, notamment le THC, la coca茂ne et le fentanyl.
Lifeloc a 茅t茅 approuv茅e pour 锚tre cot茅e sur le palier de march茅 OTCID, passant de l'OTC Pink Current Market 脿 compter du 1er juillet 2025.
Lifeloc Technologies (OTCID:LCTC), Hersteller von Atemalkohol- und Drogentestger盲ten, meldete die Finanzzahlen f眉r das 2. Quartal 2025 mit einem Nettoumsatz von $2.219 million, was einem R眉ckgang von 7% im Jahresvergleich entspricht, und einem Nettoverlust von 394.000 $ bzw. 0,14 $ je Aktie.
Das Unternehmen hielt eine Bruttomarge von 41,7% und investierte gleichzeitig stark in F&E (623.000 $) f眉r die SpinDx-Entwicklung. Die strategische Ausrichtung bleibt auf der SpinDx-Technologieplattform f眉r die schnelle Drogenerkennung, mit einem geplanten kommerziellen Start Anfang 2026. Die Plattform hat nachweislich mehrere Drogen, darunter THC, Kokain und Fentanyl, zuverl盲ssig erkannt.
Lifeloc wurde f眉r den Handel auf der OTCID-Marktstufe zugelassen und stieg damit ab dem 1. Juli 2025 vom OTC Pink Current Market auf.
- Gross margin remained stable at 41.7% despite inflation and tariff costs
- SpinDx technology successfully validated against LCMS standards for multiple drug detection
- Beta testing beginning for SpinDx oral fluid testing system
- Upgrade to OTCID market tier may improve market liquidity
- L-series devices gaining market penetration with new features and certifications
- Revenue declined 7% year-over-year to $2.219 million
- Net loss increased to $(394) thousand from $(298) thousand year-over-year
- High R&D expenses of $623 thousand impacting profitability
- Additional financing may be required to complete development plans
- Cash position decreased to $995,750 from $1,243,746 in December 2024
WHEAT RIDGE, CO / / August 11, 2025 / Lifeloc Technologies, Inc. (OTCID:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2025.
Second Quarter Financial Highlights
Lifeloc posted quarterly net revenue of
We believe our core alcohol detection product line-up is strong. The L-series LX9 and LT7 units have features and performance that are driving market penetration by meeting previously unaddressable market needs, such as smart phone pairing, wider temperature use ranges and fast customization that incorporates local languages. We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as SAI's (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors. We continue to evolve the capability and add certifications of these units to create more value and gain market share. Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal庐 automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and contributes to market share gains across the board, especially for our workplace Phoenix庐 6.0 BT and EV 30 devices.
We believe our most important goal and best opportunity remains the convergence of the global need for rapid detection of drugs of abuse with Lifeloc's proven capability to build easy-to-use portable testing equipment. We are therefore focusing our research and development efforts on leveraging the SpinDx鈩� technology platform, sometimes referred to as "Lab on a Disk," to develop a series of devices and tests that can be used at roadside and in emergency rooms, forensic labs and workplace test sites to achieve a rapid and quantitative measure for a panel of drugs of abuse. SpinDx has been demonstrated in our laboratory to effectively detect for delta-9-THC, cocaine, fentanyl, amphetamine, methamphetamine, morphine, MDMA, and benzodiazepines. Testing has validated the SpinDx measurement technology against the definitive standard liquid chromatography-mass spectroscopy (LCMS) measurement utilizing human samples. The LCMS data have validated the SpinDx test results on real-world human saliva tests at a limit of detection of approximately 10 ng/ml. With our research and development work, we continue to improve our technology's robustness, speed, and convenience of operation. We are currently updating disk design to accomplish the entire analysis on the disk as well as optimizing drug assays.
We are beginning beta testing of our SpinDx oral fluid testing system utilizing the delta-9-THC only tests using a prototype reader as shown in the photograph below. An agreement for beta testing is in place, and the test logistics are being finalized. The initial product release is projected to be a device with a disk that allows for detection of delta-9-THC (the major intoxicating component of the cannabis plant) from a test subject's oral fluid, followed by a disk for a panel of other drugs. Commercial launch of our first SpinDx application is projected to occur in early 2026. Following initial commercialization, we expect more offerings from this technology platform to include expanded drug panels and samples collected from blood and breath. Following the release of our SpinDx oral fluid testing system, we expect to accelerate development of combining our LX9 breathalyzer with the THC SpinDx detection unit, to produce our roadside marijuana breathalyzer system. The current pace of development may require additional financing to complete.
"SpinDx prototypes are starting to travel to trade shows for key customer demonstrations. We are pleased to build customer engagement as the product gets closer to launch. We have identified rapid drug testing as our biggest growth opportunity, and we believe that SpinDx will play an important role in addressing this unmet market need," commented Dr. Wayne Willkomm, President and CEO.
Additionally, in alignment with the evolving structure of the OTC Markets, Lifeloc has been approved for trading on the OTCID, which is the new market tier of the OTC Markets, and trading commenced July 1, 2025. OTCID is the replacement for fully reporting companies from the OTC Pink Current Market, which ceased on the same date. The new OTCID standards may create greater market confidence than the OTC Pink and allow a more liquid marketplace for our shareholders.
About Lifeloc Technologies
Lifeloc Technologies, Inc. (OTCID:LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, .
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, market liquidity for our shares, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our .
Phoenix庐 and Easycal庐 are registered trademarks of Lifeloc Technologies, Inc.
SpinDx鈩� is a trademark of Sandia Corporation.
Amy Evans
Lifeloc Technologies, Inc.
(303) 431-9500
LIFELOC TECHNOLOGIES, INC. | ||||||||
Condensed Balance Sheets (Unaudited) | ||||||||
ASSETS | ||||||||
June 30, 2025 (Unaudited) | December 31, 2024 | |||||||
CURRENT ASSETS: | ||||||||
Cash and cash equivalents | $ | 995,750 | $ | 1,243,746 | ||||
Accounts receivable, net | 765,730 | 732,541 | ||||||
Inventories, net | 2,988,752 | 2,996,397 | ||||||
Federal and state income taxes receivable | 55,531 | 80,560 | ||||||
Prepaid expenses and other | 160,079 | 40,045 | ||||||
Total current assets | 4,965,842 | 5,093,289 | ||||||
PROPERTY, PLANT AND EQUIPMENT: | ||||||||
Land | 317,932 | 317,932 | ||||||
Building | 1,928,795 | 1,928,795 | ||||||
AG真人官方-time Alcohol Detection And Recognition equipment and software | 569,448 | 569,448 | ||||||
Production equipment, software and space modifications | 1,349,839 | 1,349,839 | ||||||
Training courses | 432,375 | 432,375 | ||||||
Office equipment, software and space modifications | 254,333 | 254,333 | ||||||
Sales and marketing equipment and space modifications | 231,818 | 226,356 | ||||||
Research and development equipment, software and space modifications | 805,012 | 787,664 | ||||||
Research and development equipment, software and space modifications not in service | 347,448 | 128,007 | ||||||
Less accumulated depreciation | (3,826,061 | ) | (3,613,452 | ) | ||||
Total property and equipment, net | 2,410,939 | 2,381,297 | ||||||
OTHER ASSETS: | ||||||||
Patents, net | 74,913 | 78,723 | ||||||
Deposits and other | 12,261 | 12,261 | ||||||
Deferred income taxes | 1,159,199 | 1,159,199 | ||||||
Total other assets | 1,246,373 | 1,250,183 | ||||||
Total assets | $ | 8,623,154 | $ | 8,724,769 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
CURRENT LIABILITIES: | ||||||||
Accounts payable | $ | 393,046 | $ | 251,627 | ||||
Term loan payable, current portion | 54,016 | 53,195 | ||||||
Subordinated debentures payable, current portion | 16,645 | - | ||||||
Customer and tenant deposits | 37,628 | 43,814 | ||||||
Accrued expenses | 349,397 | 293,981 | ||||||
Deferred revenue, current portion | 58,862 | 54,458 | ||||||
Product warranty reserve | 46,500 | 46,500 | ||||||
Total current liabilities | 956,094 | 743,575 | ||||||
TERM LOAN PAYABLE, net of current portion and | ||||||||
debt issuance costs | 1,086,062 | 1,119,152 | ||||||
SUBORDINATED DEBENTURES PAYABLE, net of current portion and | ||||||||
debt issuance costs | 687,041 | 630,000 | ||||||
DEFERRED REVENUE, net of current portion | 6,105 | 6,165 | ||||||
Total liabilities | 2,735,302 | 2,498,892 | ||||||
COMMITMENTS AND CONTINGENCIES (Note 6) | ||||||||
STOCKHOLDERS' EQUITY: | ||||||||
Common stock, no par value; 50,000,000 shares authorized, 2,752,616 | ||||||||
shares outstanding (2,664,116 outstanding at December 31, 2024) | 5,934,314 | 5,586,014 | ||||||
Retained earnings (deficit) | (46,462 | ) | 639,863 | |||||
Total stockholders' equity | 5,887,852 | 6,225,877 | ||||||
Total liabilities and stockholders' equity | $ | 8,623,154 | $ | 8,724,769 | ||||
LIFELOC TECHNOLOGIES, INC. | ||||||||
Condensed Statements of (Loss) (Unaudited) | ||||||||
Three Months Ended June 30, | ||||||||
REVENUES: | 2025 | 2024 | ||||||
Product sales | $ | 2,191,260 | $ | 2,370,433 | ||||
Royalties | 19,800 | 8,824 | ||||||
Rental income | 8,316 | 8,073 | ||||||
Total | 2,219,376 | 2,387,330 | ||||||
COST OF SALES | 1,294,777 | 1,393,734 | ||||||
GROSS PROFIT | 924,599 | 993,596 | ||||||
OPERATING EXPENSES: | ||||||||
Research, development, and sustaining engineering | 623,262 | 662,276 | ||||||
Sales and marketing | 339,528 | 365,374 | ||||||
General and administrative | 340,074 | 363,008 | ||||||
Total | 1,302,864 | 1,390,658 | ||||||
OPERATING (LOSS) | (378,265 | ) | (397,062 | ) | ||||
OTHER INCOME (EXPENSE): | ||||||||
Interest income | 10,931 | 8,677 | ||||||
Interest expense | (26,305 | ) | (10,057 | ) | ||||
Total | (15,374 | ) | (1,380 | ) | ||||
NET (LOSS) BEFORE PROVISION FOR TAXES | (393,639 | ) | (398,442 | ) | ||||
BENEFIT FROM FEDERAL AND STATE INCOME TAXES | - | 100,454 | ||||||
NET INCOME (LOSS) | $ | (393,639 | ) | $ | (297,988 | ) | ||
NET INCOME (LOSS) PER SHARE, BASIC | $ | (0.14 | ) | $ | (0.12 | ) | ||
NET INCOME (LOSS) PER SHARE, DILUTED | $ | (0.14 | ) | $ | (0.12 | ) | ||
WEIGHTED AVERAGE SHARES, BASIC | 2,752,616 | 2,454,116 | ||||||
WEIGHTED AVERAGE SHARES, DILUTED | 2,752,616 | 2,454,116 | ||||||
LIFELOC TECHNOLOGIES, INC. | ||||||||
Condensed Statements of (Loss) (Unaudited) | ||||||||
Six Months Ended June 30, | ||||||||
REVENUES: | 2025 | 2024 | ||||||
Product sales | $ | 4,454,307 | $ | 4,504,867 | ||||
Royalties | 25,471 | 19,760 | ||||||
Rental income | 16,632 | 16,146 | ||||||
Total | 4,496,410 | 4,540,773 | ||||||
COST OF SALES | 2,663,245 | 2,711,870 | ||||||
GROSS PROFIT | 1,833,165 | 1,828,903 | ||||||
OPERATING EXPENSES: | ||||||||
Research, development, and sustaining engineering | 1,092,942 | 1,217,875 | ||||||
Sales and marketing | 674,084 | 710,383 | ||||||
General and administrative | 724,952 | 677,934 | ||||||
Total | 2,491,978 | 2,606,192 | ||||||
OPERATING (LOSS) | (658,813 | ) | (777,289 | ) | ||||
OTHER INCOME (EXPENSE): | ||||||||
Interest income | 23,288 | 26,349 | ||||||
Interest expense | (50,800 | ) | (20,207 | ) | ||||
Total | (27,512 | ) | 6,142 | |||||
NET (LOSS) BEFORE PROVISION FOR TAXES | (686,325 | ) | (771,147 | ) | ||||
BENEFIT FROM FEDERAL AND STATE INCOME TAXES | - | 189,353 | ||||||
NET INCOME (LOSS) | $ | (686,325 | ) | $ | (581,794 | ) | ||
NET INCOME (LOSS) PER SHARE, BASIC | $ | (0.25 | ) | $ | (0.24 | ) | ||
NET INCOME (LOSS) PER SHARE, DILUTED | $ | (0.25 | ) | $ | (0.24 | ) | ||
WEIGHTED AVERAGE SHARES, BASIC | 2,723,768 | 2,454,116 | ||||||
WEIGHTED AVERAGE SHARES, DILUTED | 2,723,768 | 2,454,116 | ||||||
LIFELOC TECHNOLOGIES, INC. | ||||||||||||||||
Condensed Statements of Changes in Stockholders' Equity (Unaudited) | ||||||||||||||||
For The Six Months Ended June 30, 2025 and 2024 | ||||||||||||||||
2024 | ||||||||||||||||
Common Stock Shares | Common Stock Amount | Retained Earnings | Total | |||||||||||||
Beginning balance December 31, 2023 | 2,454,116 | $ | 4,668,014 | $ | 1,692,811 | $ | 6,360,825 | |||||||||
Issuance of shares from option exercise | - | - | - | - | ||||||||||||
Warrants issued with subordinated | ||||||||||||||||
debenture | - | - | - | - | ||||||||||||
Net (loss) | - | - | (283,806 | ) | (283,806 | ) | ||||||||||
Ending balance, March 31, 2024 | 2,454,116 | 4,668,014 | 1,409,005 | 6,077,019 | ||||||||||||
Net (loss) | - | - | (297,988 | ) | (297,988 | ) | ||||||||||
Ending balance, June 30, 2024 | 2,454,116 | $ | 4,668,014 | $ | 1,111,017 | $ | 5,779,031 | |||||||||
2025 | ||||||||||||||||
Common Stock Shares | Common Stock Amount | Retained Earnings | Total | |||||||||||||
Beginning balance December 31, 2024 | 2,664,116 | $ | 5,586,014 | $ | 639,863 | $ | 6,225,877 | |||||||||
Issuance of shares from option exercise | 88,500 | 336,300 | - | 336,300 | ||||||||||||
Warrants issued with subordinated | ||||||||||||||||
debenture | - | 12,000 | - | 12,000 | ||||||||||||
Net (loss) | - | - | (292,686 | ) | (292,686 | ) | ||||||||||
Ending balance, March 31, 2025 | 2,752,616 | 5,934,314 | 347,177 | 6,281,491 | ||||||||||||
Net (loss) | - | - | (393,639 | ) | (393,639 | ) | ||||||||||
Ending balance, June 30, 2025 | 2,752,616 | $ | 5,934,314 | $ | (46,462 | ) | $ | 5,887,852 | ||||||||
LIFELOC TECHNOLOGIES, INC. | |||||||||
Condensed Statements of Cash Flows (Unaudited) | |||||||||
Six Months Ended June 30, | |||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | 2025 | 2024 | |||||||
Net (loss) | $ | (686,325 | ) | $ | (581,794 | ) | |||
Adjustments to reconcile net income (loss) to net cash | |||||||||
(used in) operating activities- | |||||||||
Depreciation and amortization | 216,419 | 114,619 | |||||||
Provision for doubtful accounts, net change | - | (3,175 | ) | ||||||
Provision for inventory obsolescence, net change | - | (35,000 | ) | ||||||
Deferred taxes, net change | - | (189,353 | ) | ||||||
Amortization of debt issuance costs | 5,886 | - | |||||||
Changes in operating assets and liabilities- | |||||||||
Accounts receivable | (33,189 | ) | (16,200 | ) | |||||
Inventories | 7,645 | 97,763 | |||||||
Federal and state income taxes receivable | 25,029 | (40,280 | ) | ||||||
Prepaid expenses and other | (120,034 | ) | (70,961 | ) | |||||
Deposits and other | - | 76,367 | |||||||
Accounts payable | 141,419 | 57,329 | |||||||
Income taxes payable | - | (44,952) | |||||||
Customer and tenant deposits | (6,186 | ) | (26,804 | ) | |||||
Accrued expenses | 55,416 | (40,896 | ) | ||||||
Deferred revenue | 4,344 | (18,972 | ) | ||||||
Net cash (used in) operating | |||||||||
activities | (389,576) | (722,309) | |||||||
CASH FLOWS (USED IN) INVESTING ACTIVITIES: | |||||||||
Purchases of property and equipment | (22,810 | ) | (263,937 | ) | |||||
Purchases of research and development equipment, software and | |||||||||
space modifications not in service | (219,441) | (227,354) | |||||||
Patent filing expense | - | (21,708 | ) | ||||||
Net cash (used in) investing activities | (242,251) | (512,999) | |||||||
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES: | |||||||||
Principal payments made on term loan | (27,469 | ) | (26,671 | ) | |||||
Proceeds from issuance of subordinated debenture | 75,000 | - | |||||||
Issuance of shares from option exercise | 336,300 | - | |||||||
Net cash provided from (used in) financing | |||||||||
activities | 383,831 | (26,671) | |||||||
NET (DECREASE) IN CASH | (247,996 | ) | (1,261,979 | ) | |||||
CASH, BEGINNING OF PERIOD | 1,243,746 | 1,766,621 | |||||||
CASH, END OF PERIOD | $ | 995,750 | $ | 504,642 | |||||
SUPPLEMENTAL INFORMATION: | |||||||||
Cash paid for interest | $ | 44,914 | $ | 18,105 | |||||
Cash paid for income tax | $ | 150 | $ | 40,280 | |||||
Income tax refund received | $ | 25,179 | $ | - | |||||
Non-cash financing and investing activities: warrants issued | |||||||||
with subordinated debenture | $ | 12,000 | $ | - | |||||
SOURCE: Lifeloc Technologies, Inc.
View the original on ACCESS Newswire
FAQ
What were Lifeloc's (LCTC) Q2 2025 earnings results?
When will Lifeloc launch its SpinDx drug testing platform?
What drugs can Lifeloc's SpinDx technology detect?
How did Lifeloc's gross margin perform in Q2 2025?
What is Lifeloc's new trading market status?
